H.C. Wainwright analyst Ed Arce raised the firm’s price target on CymaBay to $12 from $10 and keeps a Buy rating on the shares. On yesterday’s earnings call, management focused on the breadth of clinical and real-world data on seladelpar in the treatment of primary biliary cholangitis, the analyst tells investors in a research note. The firm continues to have "high confidence" in seladelpar, especially based on ENHANCE data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CBAY:
- CymaBay reports Q4 EPS (30c), consensus (30c)
- CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
- CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
- CymaBay initiated with a Buy at BTIG
- CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference